What is happening with Becton Dickinson?
Becton, Dickinson and Company (BDX) is projected to release its Q3 fiscal 2026 earnings before the market opens on Thursday, August 6, 2026. Analysts expect the company to report earnings of $3.14 per share on revenue of approximately $4.887 billion. The market is closely monitoring this announcement to see how it aligns with the company's full-year EPS guidance of $12.52 to $12.72, especially following the company's performance in its previous quarter, where it successfully beat consensus estimates for both revenue and earnings.
Related FAQs
Equity analysts covering Becton, Dickinson and Company (NYSE: BDX) maintain a stable Moderate Buy outlook, projecting steady capital appreciation supported by defensive healthcare demand, essential medical technology portfolios, and recurring consuma...
BDX (referring to Becton, Dickinson and Company, commonly known as BD, which trades on the New York Stock Exchange under the ticker symbol BDX) is a global medical technology company headquartered in Franklin Lakes, New Jersey, United States.
Evaluating whether Becton, Dickinson and Company (commonly known as BD, traded under the ticker BDX) is a good investment requires examining its standing as a premier global medical technology enterprise.
Yes, Beacon Bank offers Zelle. Customers can access the service directly through the bank's mobile application to send and receive money securely.
Becton Dickinson (BDX) recently made headlines on July 31, 2026, when it announced a voluntary recall of select lots of its BD Intraosseous Vascular Access System Needle Sets.
Yes, in 2025, the institution formerly known as Beal Bank officially rebranded as Monet Bank.
Becton, Dickinson and Company (BDX) is widely regarded as a high-quality, exceptionally reliable global medical technology enterprise with a foundational role in international healthcare infrastructure.
Bechtel Corporation operates as a massive privately held, family-controlled engineering, procurement, and construction enterprise with annual revenues exceeding $22 billion to $23 billion USD.
Becton, Dickinson and Company (commonly known as BD) is an entirely legitimate, highly respected, and globally established multinational medical technology corporation.
Becton, Dickinson and Company (commonly known as BD) is headquartered in Franklin Lakes, New Jersey, United States.
Thermo Fisher Scientific distributes regular quarterly cash dividend payments to its eligible equity investors, aligning its capital allocation strategy with consolidated operational revenues, free cash flow generation, and long-term financial growth...
The stock ticker symbol and corporate abbreviation BDX represents Becton, Dickinson and Company (widely known as BD), which is a massive global medical technology enterprise.
Becton, Dickinson and Company maintains strong future potential anchored by its global leadership in medical technology, diagnostic systems, and medication delivery solutions.
Determining whether Becton, Dickinson and Company (BDX) represents a good purchase depends heavily on an investor's focus on defensive stability, income generation, and long-term portfolio growth.
Yes, Becton, Dickinson and Company (BDX) is an official constituent of the S&P 500 Index, representing a prominent anchor within the healthcare sector tracking group.
Becton, Dickinson and Company (BDX) maintains a solid and constructive market outlook, backed by a general consensus buy rating among healthcare equity analysts.